This phase II trial is evaluating ABT414 alone and in combination with chemotherapy for patients with recurrent glioblastoma.
This trial is treating patients with Glioblastoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment, but your cancer has come back.
You may be excluded from this trial if:
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma: A Randomized Phase II Study of the EORTC Brain Tumor Group
This study is to evaluate the efficacy and safety of ABT-414 alone or with temozolomide versus temozolomide or lomustine alone in participants with recurrent glioblastoma multiforme.
**Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas**
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More